One Eleven Interactive, Inc

Innovative marketing programs for the pharmaceutical industry

One Eleven Interactive, Inc Contact Pfizer and Teva Pharmaceuticals to join Teva in Pfizer-TEVA merger

Pfizer and Teva Pharmaceuticals to join Teva in Pfizer-TEVA merger



Teva Pharma and Pfizer are in a merger that could boost Pfizer’s pharma profits.

The deal, which is valued at $14.4bn, is expected to be completed in the second quarter of 2019, after a two-year bidding process, the two companies said on Thursday.

The company said the deal would enable Pfizer to “continue its growth and expand its portfolio of products, including a range of therapeutic and investigational products for human therapeutics and human diagnostic diagnostics”.

Pfizer is in talks with Teva, which has a 30 per cent stake in the two-billion-dollar business.

The agreement will allow Pfizer “to continue its growth in the area of therapeutics in areas including immunotherapies, human therapeuticals and immunotherapeutics”, the company said in a statement.

Pfizers shares have fallen about 25 per cent since the start of the year.

Pfizer and Teva Pharmaceuticals to join Teva in Pfizer-TEVA merger



Teva Pharma and Pfizer are in a merger that could boost Pfizer’s pharma profits.

The deal, which is valued at $14.4bn, is expected to be completed in the second quarter of 2019, after a two-year bidding process, the two companies said on Thursday.

The company said the deal would enable Pfizer to “continue its growth and expand its portfolio of products, including a range of therapeutic and investigational products for human therapeutics and human diagnostic diagnostics”.

Pfizer is in talks with Teva, which has a 30 per cent stake in the two-billion-dollar business.

The agreement will allow Pfizer “to continue its growth in the area of therapeutics in areas including immunotherapies, human therapeuticals and immunotherapeutics”, the company said in a statement.

Pfizers shares have fallen about 25 per cent since the start of the year.

TopBack to Top